ADMA Biologics (NASDAQ:ADMA) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a strong sell rating to a hold rating in a report released on Wednesday morning,Zacks reports.

Several other research analysts have also recently issued reports on ADMA. Raymond James Financial started coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Mizuho cut their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Finally, Canaccord Genuity Group lowered their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $9.58 on Wednesday. The firm has a fifty day simple moving average of $9.13 and a two-hundred day simple moving average of $10.31. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $20.46. The company has a market capitalization of $2.15 billion, a PE ratio of 13.69 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.ADMA Biologics’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.14 EPS. Research analysts expect that ADMA Biologics will post 0.78 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in ADMA. Royal Bank of Canada increased its position in ADMA Biologics by 112.7% during the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after purchasing an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter worth about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of ADMA Biologics by 59.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after purchasing an additional 305,064 shares in the last quarter. Norges Bank bought a new stake in shares of ADMA Biologics during the 2nd quarter valued at about $549,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of ADMA Biologics by 385.8% during the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares during the period. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.